ADAR1 Capital Management, LLC, 10% Owner at Rallybio Corp (RLYB), bought 155,905 shares at $13.90 ($2.2M) on 2026-05-04, disclosed to the SEC on 2026-05-06.
ADAR1 Capital Management executed the largest insider purchase in Rallybio's history by buying 3,900 shares at $13.90, signaling confidence in the biotech's strategic pivot. This move comes as the stock has surged 211.98% over the last 90 days, pushing it within 0.41% of its 52-week high.
RLYB has rallied 211.98% over the last 90 days and is currently trading at $14.51, just 0.41% below its 52-week high of $14.57.
The acquisition of Candid Therapeutics, announced on March 3, 2026, is a key catalyst as the combined cash balance is projected to fund operations through 2030. Additionally, Candid is set to go public via a reverse merger with RallyBio on March 2, 2026.
The stock carries significant risk with a short interest of 35.77% of the float, which could lead to volatility if the bullish momentum reverses. Furthermore, the company is trading at a negative forward P/E of -2.72, indicating continued losses despite the recent price surge.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.90 | 3,900 | $54K | 2.5% |
| 2 | $13.97 | 116,904 | $1.6M | 75.0% |
| 3 | $14.00 | 35,101 | $491K | 22.5% |
| Total | $13.97 avg | 155,905 | $2.2M | 100% |
| Filing → |
| INM | BUY | 2026-10-05 | $57K | — | Filing → |
| INM | BUY | 2026-09-16 | $118K | — | Filing → |
| TENX | BUY | 2026-09-08 | $1.6M | — | Filing → |